Non-Vascular Stents Market is expected to be valued at US$ 1.9 billion by 2032 | FMI

 The Non-Vascular Stents Market is expected to grow at a CAGR of 4.5% over the anticipated timeframe. (2022 – 2032). In 2022, it is projected that the industry will be worth US$ 1.21 billion, and by 2032, it will be worth US$ 1.9 billion.

The global non-vascular stents market is expected to move forward in response to the growing demand for minimally-invasive procedures. Rising technological and material advancements are assisting in the development of specially designed stents for use in a variety of indications thereby fueling the overall non-vascular stents market growth.

To learn more about this report @ https://www.futuremarketinsights.com/reports/non-vascular-stents-market

Non-vascular stents use small, precise incisions, resulting in scars that are smaller and less visible than those left by traditional surgical techniques, putting the patient’s safety in jeopardy. Such surgery is associated with a faster recovery period, resulting in a shorter hospital stay for the patient, encouraging many to opt for the same.

Furthermore, patients are less likely to contract hospital-acquired illnesses like bloodstream infections and urinary tract infections if they stay in the hospital for a shorter period of time, in turn, propelling the demand for non-vascular stents.

The most visible and prominent factor spiking the sales of non-vascular stents is a surge in cases of chronic obstructive pulmonary disease (COPD), which is caused by smoking, lung cancer, tracheobronchial malacia, and chemical exposure.

Numerous innovations are taking place in the non-vascular stents market as new medical devices are developed to track gastrointestinal tract, urinary tract, and airway tract.

Non-vascular stents market trends are fostered by rising healthcare spending in developing countries, government and private insurance companies’ helpful medical reimbursement policies, and the proliferation of hospitals and ambulatory surgical centers.

The non-vascular stents market is segmented by product type and by region, where by product type, the market is divided into gastrointestinal stents, pulmonary stents, urological stents, and others.

Non-vascular implants are medical devices designed to keep open and support non-vascular structures within the body. Unlike vascular stents, which are used to treat blockages in blood vessels, non-vascular stents are used to treat a variety of conditions in other parts of the body.

Key Takeaways:

• Based on product type, the urological stents segment is likely to dominate the non-vascular stents market with a CAGR of 4.3% through 2032.
• The US non-vascular stents market is expected to capture a sizeable non-vascular stents market share accounting for around US$659.1 million by 2032.
• By 2032, the UK non-vascular stents market is expected to be valued at US$ 80.6 million, growing at a CAGR of 3.3%.
• With a CAGR of 3.6% during the forecast period, China non-vascular stents market size is predicted to be apprised at US$ 128.1 million by 2032.
• The Japan non-vascular stents market, with a CAGR of 3.9%, is projected to garner a worth of US$ 109.8 million by 2032.

Key Players:

• Medtronic plc.
• Glaukos Corporation
• Boston Scientific Corporation
• ELLA – CS, s.r.o.
• CONMED Corporation

Key Segments

By Product:

• Gastrointestinal Stents
• Biliary
• Duodenal
• Colonic
• Pancreatic
• Oesophageal Stents
• Pulmonary Stents
• Silicone Airway
• Metallic Airway
• Urological Stents
• Others